Suppr超能文献

OviTex增强组织基质在疝修补术中的临床结局:一项系统评价和荟萃分析。

Clinical outcome of OviTex reinforced tissue matrix in hernia repair: A systematic review and meta-analysis.

作者信息

Al-Qudimat Ahmad R, Altahtamouni Seif B, Singh Kalpana, Aboumarzouk Omar M, Elakkad Mohamed

机构信息

Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.

Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.

出版信息

Qatar Med J. 2025 Feb 17;2025(1):22. doi: 10.5339/qmj.2025.22. eCollection 2025.

Abstract

This review provides a comprehensive and current overview of the clinical outcomes associated with the use of OviTex reinforced tissue matrix (RTM) in hernia repair. We conducted a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Our search included research publications related to clinical outcomes involving the use of OviTex RTM in hernia repair up to August 2023. We extensively examined and extracted relevant data from databases such as Embase, PubMed, and Scopus. The meta-analysis included comparisons related to body mass index (BMI) in hernia treatment, primary abdominal wall hernias treated with OviTex, and other relevant factors. The quality of the included studies was assessed using the MINORS (Methodological Index for Non-Randomized Studies) scale. Our systematic review protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews) under registration number CRD42023456009. A total of 9 observational studies involving 990 patients from three countries (USA, Netherlands, and Germany) were included in our study. Pooled results show that the risk of the OviTex group was lower than that of the comparison group (pooled risk ratio (RR) = 0.84; 95% confidence interval (CI): 0.67-1.05;  = -1.514;  = 0.13). The prevalence rate of primary abdominal wall hernia among the included studies ranged from a minimum of 43% (95% CI: 30-58) to a maximum of 81% (95% CI: 64-91%), the risk was not significantly higher in the comparison group compared with the OviTex group (pooled RR = 1.11; 95% CI: 0.29-4.30;  = 0.155;  = 0.877), the prevalence of laparoscopic surgery was 12% (95% CI: 6-19%), the BMI was favorable in the comparison group but was not statistically significant (mean difference = 25; 95% CI: -0.02, 0.52;  = 0.073). OviTex RTM has shown promising outcomes in abdominal wall reconstruction and hernia repair. However, it is crucial to conduct further research and clinical studies to confirm these findings and unlock the capabilities of OviTex across different medical scenarios.

摘要

本综述全面且及时地概述了使用OviTex增强组织基质(RTM)进行疝修补术的临床结果。我们根据系统评价和荟萃分析的首选报告项目(PRISMA)指南进行了系统评价和荟萃分析。我们的检索范围包括截至2023年8月与使用OviTex RTM进行疝修补术的临床结果相关的研究出版物。我们广泛检查并从Embase、PubMed和Scopus等数据库中提取了相关数据。荟萃分析包括疝治疗中与体重指数(BMI)、用OviTex治疗的原发性腹壁疝以及其他相关因素的比较。使用MINORS(非随机研究方法学指数)量表评估纳入研究的质量。我们的系统评价方案已在国际前瞻性系统评价注册库PROSPERO上注册,注册号为CRD42023456009。我们的研究纳入了来自三个国家(美国、荷兰和德国)的9项观察性研究,涉及990名患者。汇总结果显示,OviTex组的风险低于对照组(汇总风险比(RR)=0.84;95%置信区间(CI):0.67 - 1.05;Z = -1.514;P = 0.13)。纳入研究中原发性腹壁疝的患病率最低为43%(95%CI:30 - 58),最高为81%(95%CI:64 - 91%),与OviTex组相比,对照组的风险没有显著更高(汇总RR = 1.11;95%CI:0.29 - 4.30;Z = 0.155;P = 0.877),腹腔镜手术的患病率为12%(95%CI:6 - 19%),对照组的BMI较好,但无统计学意义(平均差异 = 25;95%CI:-0.02,0.52;P = 0.073)。OviTex RTM在腹壁重建和疝修补术中已显示出有前景的结果。然而,进行进一步的研究和临床研究以证实这些发现并挖掘OviTex在不同医疗场景中的能力至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e95/12107482/4c3cde15d83c/qmj-2025-022-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验